Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Sep-30-22 | Oct-01-21 | Oct-02-20 | Sep-27-19 | Sep-28-18 | Sep-29-17 | Sep-30-16 | Oct-02-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Medical | 674.7 | 643.8 | 584.5 | 596.8 | 602.0 | 556.9 | 505.8 | 534.3 |
| United States | 263.7 | 262.3 | 249.8 | 275.3 | 268.8 | 231.9 | 216.5 | |
| Industrial | 184.7 | 174.3 | 153.8 | 183.8 | 171.4 | 141.2 | 114.3 | 98.0 |
| Latin America | | | | | 7.0 | 7.9 | 8.2 | |
| Total revenues | 859.4 | 818.1 | 738.3 | 780.6 | 463.3 | 698.1 | 620.1 | 632.3 |
| Revenue growth [+] | 5.0% | 10.8% | -5.4% | 68.5% | -33.6% | 12.6% | -1.9% | |
| Medical | 4.8% | 10.1% | -2.1% | -0.9% | 8.1% | 10.1% | -5.3% | |
| United States | 0.5% | 5.0% | -9.3% | 2.4% | 15.9% | 7.1% | | |
| Industrial | 6.0% | 13.3% | -16.3% | 7.2% | 21.4% | 23.5% | 16.6% | |
| Latin America | | | | | -11.4% | -3.7% | | |
| Cost of goods sold | 575.9 | 546.6 | 548.1 | 523.9 | 0.0 | 444.6 | 371.7 | 381.7 |
| Gross profit | 283.5 | 271.5 | 190.2 | 256.7 | 463.3 | 253.5 | 248.4 | 250.6 |
| Gross margin | 33.0% | 33.2% | 25.8% | 32.9% | 100.0% | 36.3% | 40.1% | 39.6% |
| Selling, general and administrative | 118.3 | 125.5 | 142.2 | 128.1 | 209.4 | 102.5 | 85.8 | 72.7 |
| Research and development | 77.0 | 71.9 | 78.9 | 78.1 | | 67.3 | 53.5 | 50.4 |
| Other operating expenses | | | | | 247.0 | | | |
| EBITDA [+] | 121.8 | 111.4 | 8.6 | 89.7 | 49.1 | 111.1 | 124.4 | 139.8 |
| EBITDA growth | 9.3% | 1195.3% | -90.4% | 82.7% | -55.8% | -10.7% | -11.0% | |
| EBITDA margin | 14.2% | 13.6% | 1.2% | 11.5% | 10.6% | 15.9% | 20.1% | 22.1% |
| Depreciation | 19.0 | 20.5 | 22.3 | 23.5 | 26.0 | 16.9 | 9.8 | 9.6 |
| EBITA | 102.8 | 90.9 | -13.7 | 66.2 | 23.1 | 94.2 | 114.6 | 130.2 |
| EBITA margin | 12.0% | 11.1% | -1.9% | 8.5% | 5.0% | 13.5% | 18.5% | 20.6% |
| Amortization of intangibles | 14.6 | 16.8 | 17.2 | 15.7 | 16.2 | 10.5 | 5.5 | 2.7 |
| EBIT [+] | 88.2 | 74.1 | -30.9 | 50.5 | 6.9 | 83.7 | 109.1 | 127.5 |
| EBIT growth | 19.0% | -339.8% | -161.2% | 631.9% | -91.8% | -23.3% | -14.4% | |
| EBIT margin | 10.3% | 9.1% | -4.2% | 6.5% | 1.5% | 12.0% | 17.6% | 20.2% |
| Non-recurring items [+] | | | 2.8 | 4.8 | | | | |
| Asset impairment | | | 2.8 | 4.8 | | | | |
| Interest expense, net [+] | 39.4 | 42.0 | 31.3 | 21.0 | -0.2 | 12.1 | 1.6 | 0.7 |
| Interest expense | 39.8 | 42.1 | 31.4 | 21.1 | 21.7 | 12.3 | 1.9 | 1.2 |
| Interest income | 0.4 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.5 |
| Other income (expense), net | -4.3 | -3.5 | -7.6 | -3.2 | 40.3 | 3.2 | -2.5 | 0.8 |
| Pre-tax income | 44.5 | 28.6 | -72.6 | 21.5 | 25.7 | 74.8 | 105.0 | 127.6 |
| Income taxes | 13.7 | 10.7 | -15.2 | 5.7 | -2.6 | 22.8 | 36.0 | 46.8 |
| Tax rate | 30.8% | 37.4% | 20.9% | 26.5% | | 30.5% | 34.3% | 36.7% |
| Minority interest | 0.5 | 0.5 | 0.5 | 0.3 | | 0.4 | 0.5 | 0.8 |
| Net income | 30.3 | 17.4 | -57.9 | 15.5 | 28.3 | 51.6 | 68.5 | 80.0 |
| Net margin | 3.5% | 2.1% | -7.8% | 2.0% | 6.1% | 7.4% | 11.0% | 12.7% |
| |
| Basic EPS [+] | $0.76 | $0.44 | ($1.49) | $0.41 | $0.75 | $1.37 | $1.83 | $2.14 |
| Growth | 72.0% | -129.7% | -467.8% | -45.7% | -45.6% | -25.1% | -14.4% | |
| Diluted EPS [+] | $0.73 | $0.43 | ($1.49) | $0.40 | $0.74 | $1.36 | $1.82 | $2.12 |
| Growth | 68.7% | -128.9% | -471.6% | -45.5% | -45.7% | -25.3% | -14.4% | |
| |
| Shares outstanding (basic) [+] | 39.8 | 39.3 | 38.8 | 38.2 | 37.9 | 37.6 | 37.4 | 37.4 |
| Growth | 1.3% | 1.3% | 1.6% | 0.8% | 0.8% | 0.5% | 0.0% | |
| Shares outstanding (diluted) [+] | 41.6 | 40.3 | 38.8 | 38.6 | 38.4 | 38.0 | 37.7 | 37.7 |
| Growth | 3.2% | 3.9% | 0.5% | 0.5% | 1.1% | 0.8% | 0.0% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|